MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells

OncoImmunology

Volumn 4, Issue 1, 2015, Pages 985924-

  Catalán, Elena ^a   Charni, Seyma ^b,c   Jaime, Paula ^d   Aguiló, Juan Ignacio ^a   Enríquez, José Antonio ^a   Naval, Javier ^a   Pardo, Julián ^d,e   Villalba, Martín ^b,c   Anel, Alberto ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b INSERM   (France)

^c HÔPITAL SAINT ELOI   (France)

^d INSTITUTO DE INVESTIGACIÓN SANITARIA ARAGÓN IIS ARAGÓN   (Spain)

^e FUNDACIÓN ARAID   (Spain)

Author keywords

cancer immunotherapy; cytotoxic T lymphocytes; dichloroacetate; glucose metabolism; NK cells; cells

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CELL METABOLISM; CHEMOLUMINESCENCE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NATURAL KILLER CELL; NONHUMAN; POLYMERASE CHAIN REACTION; TUMOR CELL;

EID: 84938702933     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.985924     Document Type: Article

References (50)

1. O.Warburg. On respiratory impairment in cancer cells. Science 1956; 124:269y-70; PMID:13351693
2. S.Charni, G.de Bettignies, M.G.Rathore, J.I.Aguiló, P.J.van den Elsen, D.Haouzi, R.A.Hipskind, J.A.Enriquez, M.Sanchez-Beato, J.Pardo Oxidative phosphorylation induces de novo expression of the MHC class I in tumor cells through the ERK5 pathway. J Immunol 2010; 185:3498-503; PMID:20729331; dx.doi.org/10.4049/jimmunol.1001250
3. C.Dunn, C.Wiltshire, A.MacLaren, D.A.F.Gillespie. Molecular mechanism and biological function of JNK signaling via the c-Jun transcription factor. Cell Signal 2002; 14:585-93; PMID:11955951; dx.doi.org/10.1016/S0898-6568(01)00275-3
4. M.Villalba, M.G.Rathore, N.López-Royuela, E.Krzywinska, J.Garaude, N.Allende-Vega. From tumor cell metabolism to tumor immune escape. Int J Biochem Cell Biol 2013; 45:106-13; PMID:22568930; dx.doi.org/10.1016/j.biocel.2012.04.024
5. J.Garaude, S.Kaminski, S.Charni, J.I.Aguiló, C.Jacquet, M.Plays, F.Rodriguez, J.Hernández, R.A.Hipskind, A.Anel Impaired anti-leukemic immune response in PKCq-deficient mice. Mol Immunol 2008; 45:3463-9; PMID:18462800; dx.doi.org/10.1016/j.molimm.2008.03.016
6. J.I.Aguiló, J.Garaude, J.Pardo, M.Villalba, A.Anel. Protein kinase C-q is required for NK cell activation and in vivo control of tumor progression. J Immunol 2009; 182:1972-81; PMID:19201850; dx.doi.org/10.4049/jimmunol.0801820
7. N.Aptsiauri, A.Cabrera, A.García-Lora, M.A.López-Nevot, F.Ruiz-Cabello, F.Garrido. MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol 2007; 256:139-89; PMID:17241907; dx.doi.org/10.1016/S0074-7696(07)56005-5
8. F.Garrido, I.Algarra, A.M.García-Lora. The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible “hard” lesions. Cancer Immunol Immunother 2010; 59:1601-6; PMID:20625726
9. E.D.Michelakis, G.Sutendra, P.Dromparis, L.Webster, A.Haromy, E.Niven, C.Maguire, T.L.Gammer, J.R.Mackey, D.Fulton Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2010; 12:31ra4; PMID:20463368
10. M.Villalba, N.López-Royuela, E.Krzywinska, M.Rathore, R.Hipskind, H.Haouas, N.Allende-Vega. Chemical metabolic inhibitors for the treatment of blood-borne cancers. Anticancer Agents Med Chem 2014; 14:223-32; PMID:24237221; dx.doi.org/10.2174/18715206113136660374
11. C.Oliveras-Ferraros, S.Cufí, A.Vázquez-Martín, O.J.Menendez, J.Bosch-Barrerra, B.Martín-Castillo, J.Joven, J.A.Menendez. Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. Cell Cycle 2012; 11:865-70; PMID:22333588; dx.doi.org/10.4161/cc.11.5.19252
12. M.Terme, E.Ullrich, N.F.Delahaye, N.Chaput, L.Zitvogel. Natural killer cell–directed therapies: moving from unexpected results to successful strategies. Nat Immunol 2008; 9:486-94; PMID:18425105; dx.doi.org/10.1038/ni1580
13. E.Vivier, E.Tomasello, M.Baratin, T.Walzer, S.Ugolini. Functions of natural killer cells. Nat Immunol 2008; 9:503-10; PMID:18425107; dx.doi.org/10.1038/ni1582
14. A.Anel, J.I.Aguiló, E.Catalán, J.Garaude, M.G.Rathore, J.Pardo, M.Villalba. Protein kinase C-q (PKC-q) in natural killer cell function and anti-tumor immunity. Front Immunol 2012; 3:187; PMID:22783260; dx.doi.org/10.3389/fimmu.2012.00187
15. M.F.Van den Broek, D.Kägi, R.M.Zinkernagel, H.Hengartner. Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur J Immunol 1995; 25:3514-6; PMID:8566046; dx.doi.org/10.1002/eji.1830251246
16. J.Pardo, S.Balkow, A.Anel, M.M.Simon. Granzymes are critically involved in NK-mediated control of RMA-S tumor growth in vivo. Eur J Immunol 2002; 32:2881-6; PMID:12355441; dx.doi.org/10.1002/1521-4141(2002010)32:10%3c2881::AID-IMMU2881%3e3.0.CO;2-K
17. L.L.Lanier. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9:495-502; PMID:18425106; dx.doi.org/10.1038/ni1581
18. L.Ruggeri, A.Mancusi, M.Capanni, E.Urbani, A.Carotti, T.Aloisi, M.Stern, D.Pende, K.Perruccio, E.Burchielli Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007; 110:433-40; PMID:17371948; dx.doi.org/10.1182/blood-2006-07-038687
19. M.Stern, L.Ruggeri, A.Mancusi, M.E.Bernardo, C.de Angelis, C.Bucher, F.Locatelli, F.Aversa, A.Velardi. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 2008; 112:2990-5; PMID:18492955; dx.doi.org/10.1182/blood-2008-01-135285
20. R.Willemze, C.A.Rodrigues, M.Labopin, G.Sanz, G.Michel, G.Socie, B.Rio, A.Sirvent, M.Renaud, L.Madero KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009; 23:492-500; PMID:19151783; dx.doi.org/10.1038/leu.2008.365
21. S.Charni, J.I.Aguiló, J.Garaude, G.de Bettignies, C.Jacquet, R.A.Hipskind, D.Singer, A.Anel, M.Villalba. ERK5 knockdown generates mouse leukemia cells with low MHC class I levels that activate NK cells and block tumorigenesis. J Immunol 2009; 182:3398-405; PMID:19265117; dx.doi.org/10.4049/jimmunol.0803006
22. S.Gamen, A.Anel, J.Montoya, I.Marzo, A.Piñeiro, J.Naval. mtDNA depleted U937 cells are sensitive to TNF- and Fas-induced cytotoxicity. FEBS Lett 1995; 376:15-8; PMID:8521957; dx.doi.org/10.1016/0014-5793(95)01236-1
23. J.I.Aguiló, A.Anel, E.Catalán, A.Sebastián, R.Acín-Pérez, J.Naval, R.Wallich, M.M.Simon, J.Pardo. Granzyme B of cytotoxic T cells induces extramitochondrial reactive oxygen species production via caspase-dependent NADPH oxidase activation. Immunol Cell Biol 2010; 88:545-54; PMID:20125115; dx.doi.org/10.1038/icb.2010.5
24. R.Acín-Pérez, M.Bayona-Bafaluy, M.Bueno, C.Machicado, P.Fernández-Silva, A.Pérez-Martos, J.Montoya, M.López-Pérez, J.Sancho, J.Enríquez. An intragenic suppressor in the cytochrome c oxidase I gene of mouse mitochondrial DNA. Hum Mol Genet 2003; 12:329-39; PMID:12554686; dx.doi.org/10.1093/hmg/ddg021
25. P.Brossart, A.W.Goldrath, E.A.Butz, S.Martin, M.J.Bevan. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 1997; 158:3270-6; PMID:9120283
26. M.E.Christensen, N.J.Waterhouse. Mechanisms of CTL cytotoxicity. A reactive response to granzyme B. Immunol Cell Biol 2010; 88:500-1; PMID:20231855; dx.doi.org/ 10.1038/icb.2010.23
27. J.Pardo, S.Balkow, A.Anel, M.M.Simon. The differential contribution of granzyme A and granzyme B in CTL-mediated apoptosis is determined by the quality of target cells. Eur J Immunol 2002; 32:1980-5; PMID:12115618; dx.doi.org/10.1002/1521-4141(200207)32:7%3c1980::AID-IMMU1980%3e3.0.CO;2-Z
28. J.Pardo, A.Bosque, R.Brehm, R.Wallich, J.Naval, A.Müllbacher, A.Anel, M.M.Simon. Apoptotic pathways are selectively activated by granzyme A and/or granzyme B in CTL-mediated target cell lysis. J Cell Biol 2004; 167:457-68; PMID:15534000; dx.doi.org/10.1083/jcb.200406115
29. M.Kasai, T.Yoneda, S.Habu, Y.Maruyama, K.Okumura, T.Tokunaga. In vivo effect of anti-asialo GM1 antibody on natural killer activity. Nature 1981; 291:334-5; PMID:7231554; dx.doi.org/10.1038/291334a0
30. S.M.Jeon, N.S.Chandel, N.Hay. AMPK regulates NADPH homeostasis to promote tumor cell survival during enery stress. Nature 2012; 485:661-5; PMID:22660331; dx.doi.org/10.1038/nature11066
31. T.Li, N.Kon, L.Jiang, M.Tan, T.Ludwig, Y.Zhao, R.Baer, W.Gu. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012; 149:1269-83; PMID:22682249; dx.doi.org/10.1016/j.cell.2012.04.026
32. S.E.Henrickson, T.R.Mempel, I.B.Mazo, B.Liu, M.N.Artyomov, H.Zheng, A.Peixoto, M.Flynn, B.Senman, T.Junt In vivo imaging of T cell priming. Sci Signal 2008; 1:pt2; PMID:18364513; dx.doi.org/10.1126/stke.112pt2
33. P.D.Holler, D.M.Kranz. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 2003; 18:255-64; PMID:12594952; dx.doi.org/10.1016/S1074-7613(03)00019-0
34. A.Veillette, M.A.Bookman, E.M.Horak, J.B.Bolen. The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck. Cell 1988; 55:301-11; PMID:3262426; dx.doi.org/10.1016/0092-8674(88)90053-0
35. P.P.Yachi, J.Ampudia, N.R.Gascoigne, T.Zal. Nonstimulatory peptides contribute to antigeninduced CD8–T cell receptor interaction at the immunological synapse. Nat Immunol 2005; 6:785-92; PMID:15980863; dx.doi.org/10.1038/ni1220
36. A.M.O'Rourke, J.Rogers, M.F.Mescher. Activated CD8 binding to class I protein mediated by the T-cell receptor results in signalling. Nature 1990; 346:187-9; PMID:2114552; dx.doi.org/10.1038/346187a0
37. N.Labrecque, L.S.Whitfield, R.Obst, C.Waltzinger, C.Benoist, D.Mathis. How much TCR does a T cell need? Immunity 2001; 15:71-82; PMID:11485739; dx.doi.org/10.1016/S1074-7613(01)00170-4
38. M.López-Botet, T.Bellón, M.Llano, F.Navarro, P.García, M.de Miguel. Paired inhibitory and triggering NK cell receptors for HLA class I molecules. Hum Immunol 2000; 61:7-17; PMID:10658973; dx.doi.org/10.1016/S0198-8859(99)00161-5
39. D.Cho, D.Campana. Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med 2009; 29:89-96; PMID:19411773; dx.doi.org/10.3343/kjlm.2009.29.2.89
40. R.McGilvray, R.Eagle, N.Watson, A.Al-Attar, G.Ball, I.Jafferji, J.Trowsdale, L.Durrant. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res 2009; 15:6993-7002; PMID:19861434; dx.doi.org/10.1158/1078-0432.CCR-09-0991
41. E.Mamessier, L.C.Pradel, M.L.Thibult, C.Drevet, A.Zouine, J.Jacquemier, G.Houvenaeghel, F.Bertucci, D.Birnbaum, D.Olive. Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets. J Immunol 2013; 190:2424-36; PMID:23359508; dx.doi.org/10.4049/jimmunol.1200140
42. G.P.Dunn, A.T.Bruce, H.Ikeda, L.J.Old, R.D.Schreiber. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8; PMID:12407406; dx.doi.org/10.1038/ni1102-991
43. A.F.Ochsenbein, S.Sierro, B.Odermatt, M.Pericin, U.Karrer, J.Hermans, S.Hemmi, H.Hengartner, R.M.Zinkernagel. Roles of tumor localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001; 411:1058-64; PMID:11429607; dx.doi.org/10.1038/35082583
44. D.Pardoll. T cells and tumors. Nature 2001; 411:1010-2; PMID:11429587
45. C.M.Koebel, W.Vermi, J.B.Swann, N.Zerafa, S.J.Rodig, L.J.Old, M.J.Smyth, R.D.Schreiber. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450:903-7; PMID:18026089; dx.doi.org/10.1038/nature06309
46. P.W.Kantoff, C.S.Higano, N.D.Shore, E.R.Berger, E.J.Small, D.F.Penson, C.H.Redfern, A.C.Ferrari, R.Dreicer, R.B.Sims Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Eng J Med 2010; 363:411-22; PMID:20818862; dx.doi.org/10.1056/NEJMoa1001294
47. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.Hassel Improved survival with ipilimumab in patients with metastatic melanoma. New Eng J Med 2010; 363:711-23; PMID:20525992; dx.doi.org/10.1056/NEJMoa1003466
48. A.Ribas. Tumor immunotherapy directed at PD-1. New Eng J Med 2012; 366:2517-9; PMID:22658126
49. S.L.Topalian, F.S.Hodi, J.R.Brahmer, S.N.Gettinger, D.C.Smith, D.F.McDermott, J.D.Powderly, R.D.Carvajal, J.A.Sosman, M.B.Atkins Safety, activity, and immune correlates of Anti–PD-1 antibody in cancer. New Eng J Med 2012; 366:2443-54; PMID:22658127; dx.doi.org/10.1056/NEJMoa1200690
50. G.G.Halfteck, M.Elboim, C.Gur, H.Achdout, H.Ghadially, O.Mandelboim. Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1. J Immunol 2009; 182:2221-30; PMID:19201876; dx.doi.org/10.4049/jimmunol.0801878